A detailed history of Trexquant Investment LP transactions in Larimar Therapeutics, Inc. stock. As of the latest transaction made, Trexquant Investment LP holds 123,066 shares of LRMR stock, worth $411,040. This represents 0.01% of its overall portfolio holdings.

Number of Shares
123,066
Previous 151,107 18.56%
Holding current value
$411,040
Previous $989,000 52.48%
% of portfolio
0.01%
Previous 0.01%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 12, 2025

SELL
$3.8 - $9.29 $106,555 - $260,500
-28,041 Reduced 18.56%
123,066 $470,000
Q3 2024

Nov 12, 2024

SELL
$6.3 - $10.68 $220,922 - $374,515
-35,067 Reduced 18.84%
151,107 $989,000
Q2 2024

Aug 13, 2024

BUY
$6.33 - $9.89 $886,073 - $1.38 Million
139,980 Added 303.03%
186,174 $1.35 Million
Q1 2024

May 14, 2024

BUY
$4.2 - $13.28 $194,014 - $613,456
46,194 New
46,194 $350,000
Q1 2023

May 15, 2023

BUY
$4.0 - $6.68 $138,412 - $231,148
34,603 New
34,603 $156,000

Others Institutions Holding LRMR

About Larimar Therapeutics, Inc.


  • Ticker LRMR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,269,200
  • Market Cap $145M
  • Description
  • Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...
More about LRMR
Track This Portfolio

Track Trexquant Investment LP Portfolio

Follow Trexquant Investment LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Trexquant Investment LP, based on Form 13F filings with the SEC.

News

Stay updated on Trexquant Investment LP with notifications on news.